Abstract 1882: MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib

MLA

Xiaodong Wang, et al. “Abstract 1882: MERTK Drives Residual Tumor Growth in EGFR-Mutated Non-Small Cell Lung Cancer Cells Treated with Osimertinib.” Cancer Research, vol. 80, Aug. 2020, p. 1882. EBSCOhost, https://doi.org/10.1158/1538-7445.am2020-1882.

APA

Xiaodong Wang, Dan Yan, Rebecca E. Parker, Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, Stephen V. Frye, Zikang Tan, & Douglas K. Graham. (2020). Abstract 1882: MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib. Cancer Research, 80, 1882. https://doi.org/10.1158/1538-7445.am2020-1882

Chicago

Xiaodong Wang, Dan Yan, Rebecca E. Parker, Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, Stephen V. Frye, Zikang Tan, and Douglas K. Graham. 2020. “Abstract 1882: MERTK Drives Residual Tumor Growth in EGFR-Mutated Non-Small Cell Lung Cancer Cells Treated with Osimertinib.” Cancer Research 80 (August): 1882. doi:10.1158/1538-7445.am2020-1882.